Skip to content

Current Debt at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
$500.4M+10,325%
GeneDx Holdings logo
GeneDx HoldingsWGS
$0-100%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
$5.8M+189%
BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN
$424K
Quest Diagnostics logo
Quest DiagnosticsDGX
$503M+50,200%

Other financials

Income statement

See full
Revenue$83.7M-4.9%
Gross profit$63.1M-11.8%
Operating income-$18.4M+34.1%
Net income-$14.5M+43.8%
EPS (diluted)-$0.49+45.6%

Balance sheet

See full
Cash & equivalents$63.8M-28.9%
Total debt$36.7M+42.1%
Total equity$461.4M+4.8%
Total assets$547.8M+9.2%

Cash flow

See full
Operating cash flow-$22.1M-267%
CapEx$12.5M+163%
Free cash flow-$34.6M-221%

Valuation

See full
Market cap$694.86M+29.9%
Enterprise value$667.82M+41.8%
P/S+0.5×

Profitability

See full
Gross margin77.9%-4.1pp
Operating margin-9.8%-30.8pp
Net margin-3.8%-10.2pp
FCF margin1.3%-10.7pp

Returns & leverage

See full
Return on equity-2.8%-10.6pp
Debt / equity0.1×0.0×
Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Castle Biosciences's current debt?
Castle Biosciences (CSTL) reported current debt of $1.67M in Q1 2026.
How has Castle Biosciences's current debt changed year-over-year?
Castle Biosciences's current debt increased by 50.0% year-over-year, from $1.11M to $1.67M.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.